Document is current
Any future updates will be listed below
-
Authors
Bright, Heber Rew Bright https://orcid.org/0000-0002-3149-5750
Phan, Duc Binh https://orcid.org/0000-0002-8916-9093
Zahid, Amna
Motedayen Aval, Leila https://orcid.org/0009-0005-7352-6454
Manupati, Shilpa
Smith, Catherine H. https://orcid.org/0000-0001-9918-1144
Exton, Lesley S. https://orcid.org/0000-0003-0073-1885
Ezejimofor, Martinsixtus https://orcid.org/0000-0002-2510-9964
Lunt, Mark
Warren, Richard B.
Yiu, Zenas Z. N. https://orcid.org/0000-0002-1831-074X
-
Funding
Funding for this research was provided by:
Psoriasis Association
- License Information
-
More Information
Article History
Received: 11 August 2025
Accepted: 16 October 2025
First Online: 31 October 2025
Declarations
:
: Richard B Warren is in receipt of either research grants and/or act as a consultant for AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DiCE, Galderma, GSK, Janssen, Lilly, Leo, Meiji Pharma, Novartis, Pfizer, RAPT pharmaceuticals, Sanofi, Sun Pharma, UCB & UNION. Richard B Warren is an Editor-in-Chief of Dermatology and Therapy . Richard Warren was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Catherine H Smith is in receipt of an NIHR Senior Investigator award and research funding as part of EC funded consortia with multiple industry partners (Biomap-imi.eu; Hippocrates-imi.eu). Lesley S Exton and Martinsixtus Ezejimofor are involved in the development of clinical guidelines for biologic therapy for psoriasis. Zenas ZN Yiu, Mark Lunt, Heber Rew Bright Bright, Duc Binh Phan, Amna Zahid, Shilpa Manupati and Leila Motedayen Aval declare that they have no competing interests.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
